These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 33377267

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of topical immunotherapy with squaric acid dibutylester for alopecia areata in Japanese patients.
    Sakai K, Fukushima S, Mizuhashi S, Jinnin M, Makino T, Inoue Y, Ihn H.
    Allergol Int; 2020 Apr; 69(2):274-278. PubMed ID: 31767273
    [Abstract] [Full Text] [Related]

  • 3. Seventeen cases of alopecia areata: combination of SADBE topical immunotherapy with other therapies.
    Morita K, Nakamura M, Nagamachi M, Kishi T, Miyachi Y.
    J Dermatol; 2002 Oct; 29(10):661-4. PubMed ID: 12433000
    [Abstract] [Full Text] [Related]

  • 4. Topical therapy of alopecia areata with squaric acid dibutylester.
    Case PC, Mitchell AJ, Swanson NA, Vanderveen EE, Ellis CN, Headington JT.
    J Am Acad Dermatol; 1984 Mar; 10(3):447-50. PubMed ID: 6725657
    [Abstract] [Full Text] [Related]

  • 5. Topical squaric acid dibutylester therapy for alopecia areata: a double-sided patient-controlled study.
    Chua SH, Goh CL, Ang CB.
    Ann Acad Med Singap; 1996 Nov; 25(6):842-7. PubMed ID: 9055014
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of the topical sensitizer squaric acid dibutyl ester in Alopecia areata and factors influencing the outcome.
    Ajith C, Gupta S, Kanwar AJ.
    J Drugs Dermatol; 2006 Mar; 5(3):262-6. PubMed ID: 16573260
    [Abstract] [Full Text] [Related]

  • 7. Hair Regrowth Outcomes of Contact Immunotherapy for Patients With Alopecia Areata: A Systematic Review and Meta-analysis.
    Lee S, Kim BJ, Lee YB, Lee WS.
    JAMA Dermatol; 2018 Oct 01; 154(10):1145-1151. PubMed ID: 30073292
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic approach with squaric acid dibutylester for steroid resistant-alopecia areata incognita: A pilot study of a single center.
    Starace M, Vezzoni R, Alessandrini A, Bruni F, Carpanese MA, Misciali C, Sechi A, Piraccini BM.
    Dermatol Ther; 2021 Sep 01; 34(5):e15096. PubMed ID: 34390608
    [Abstract] [Full Text] [Related]

  • 9. Squaric acid dibutyl ester in the treatment of alopecia areata.
    Barth JH, Darley CR, Gibson JR.
    Dermatologica; 1985 Sep 01; 170(1):40-2. PubMed ID: 3882480
    [Abstract] [Full Text] [Related]

  • 10. Childhood epidermolysis bullosa acquisita during squaric acid dibutyl ester immunotherapy for alopecia areata.
    Guerra L, Pacifico V, Calabresi V, De Luca N, Castiglia D, Angelo C, Zambruno G, Di Zenzo G.
    Br J Dermatol; 2017 Feb 01; 176(2):491-494. PubMed ID: 27208509
    [Abstract] [Full Text] [Related]

  • 11. Treatment of severe alopecia areata with squaric acid dibutylester in pediatric patients.
    Orecchia G, Malagoli P, Santagostino L.
    Pediatr Dermatol; 1994 Mar 01; 11(1):65-8. PubMed ID: 8170854
    [Abstract] [Full Text] [Related]

  • 12. Treatment of alopecia areata with squaric acid dibutylester.
    Micali G, Cicero RL, Nasca MR, Sapuppo A.
    Int J Dermatol; 1996 Jan 01; 35(1):52-6. PubMed ID: 8838932
    [Abstract] [Full Text] [Related]

  • 13. Topical immunotherapy in alopecia areata.
    Singh G, Lavanya M.
    Int J Trichology; 2010 Jan 01; 2(1):36-9. PubMed ID: 21188022
    [Abstract] [Full Text] [Related]

  • 14. Squaric acid sensitization is not required for response in the treatment of alopecia areata.
    Vedak P, Kroshinsky D.
    J Am Acad Dermatol; 2015 Sep 01; 73(3):471-6. PubMed ID: 26282797
    [Abstract] [Full Text] [Related]

  • 15. Modified immunotherapy for alopecia areata.
    Yoshimasu T, Furukawa F.
    Autoimmun Rev; 2016 Jul 01; 15(7):664-7. PubMed ID: 26932732
    [Abstract] [Full Text] [Related]

  • 16. Successful treatment of alopecia areata-like hair loss with the contact sensitizer squaric acid dibutylester (SADBE) in C3H/HeJ mice.
    Freyschmidt-Paul P, Sundberg JP, Happle R, McElwee KJ, Metz S, Boggess D, Hoffmann R.
    J Invest Dermatol; 1999 Jul 01; 113(1):61-8. PubMed ID: 10417620
    [Abstract] [Full Text] [Related]

  • 17. Topical immunomodulator therapy with squaric acid dibutylester (SADBE) is effective treatment for severe alopecia areata (AA): results of an open-label, paired-comparison, clinical trial.
    Dall'oglio F, Nasca MR, Musumeci ML, La Torre G, Ricciardi G, Potenza C, Micali G.
    J Dermatolog Treat; 2005 Feb 01; 16(1):10-4. PubMed ID: 15897160
    [Abstract] [Full Text] [Related]

  • 18. Clinical experience on the treatment of alopecia areata with squaric acid dibutyl ester.
    Giannetti A, Orecchia G.
    Dermatologica; 1983 Feb 01; 167(5):280-2. PubMed ID: 6653853
    [Abstract] [Full Text] [Related]

  • 19. Topical immunotherapy in combination with anthralin in the treatment of refractory alopecia areata.
    Kagami S, Kishi Y, Hino H.
    J Cosmet Dermatol; 2020 Sep 01; 19(9):2411-2414. PubMed ID: 32621407
    [Abstract] [Full Text] [Related]

  • 20. Delayed type hypersensitivity-induced myeloid-derived suppressor cells regulate autoreactive T cells.
    Singh V, Mueller U, Freyschmidt-Paul P, Zöller M.
    Eur J Immunol; 2011 Oct 01; 41(10):2871-82. PubMed ID: 21728175
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.